FZD10 Gene

FZD10 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD10 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 10</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD10</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 10</td></tr>
<tr><td class="label">Chromosome</td><td>12q14.1</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8372</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000111432</td></tr>
<tr><td class="label">OMIM ID</td><td>605548</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9ULW2</td></tr>
<tr><td class="label">Associated Diseases</td><td>Synovial Sarcoma, Cancer, Alzheimer's Disease, Parkinson's Disease</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

FZD10 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD10 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 10</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD10</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 10</td></tr>
<tr><td class="label">Chromosome</td><td>12q14.1</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8372</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000111432</td></tr>
<tr><td class="label">OMIM ID</td><td>605548</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9ULW2</td></tr>
<tr><td class="label">Associated Diseases</td><td>Synovial Sarcoma, Cancer, Alzheimer's Disease, Parkinson's Disease</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

FZD10 (Frizzled Class Receptor 10) is a member of the Frizzled family of seven-transmembrane G protein-coupled receptors that serve as primary receptors for Wnt ligands. While FZD10 is best characterized for its role in cancer, particularly synovial sarcoma where it is frequently overexpressed, emerging evidence indicates that FZD10 also plays important roles in neural development and is relevant to neurodegenerative disease pathogenesis. FZD10 activates both canonical Wnt/β-catenin signaling and non-canonical Wnt pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling, with distinct expression patterns in the developing and adult nervous system. In the brain, FZD10 is expressed in neural stem cells, developing neurons, and select mature neuronal populations, where it regulates neurogenesis, neuronal differentiation, and synaptic function. Dysregulated FZD10 expression and Wnt signaling alterations have been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), making FZD10 a molecule of interest for understanding neurodegeneration mechanisms and developing therapeutic strategies [@l'italien2019].

Gene Structure and Protein Architecture

The FZD10 gene is located on chromosome 12q14.1 and encodes a 695-amino acid protein with a molecular weight of approximately 77 kDa. Like other Frizzled receptors, FZD10 possesses the characteristic architecture of class F GPCRs with distinct functional domains:

Extracellular Domain

The N-terminal cysteine-rich domain (CRD) of FZD10 contains 10 conserved cysteine residues forming disulfide bonds that create a compact ligand-binding module. The CRD specifically recognizes Wnt ligands with a distinctive binding profile compared to other Frizzled receptors. Structural studies have demonstrated that FZD10 has high affinity for Wnt5A and Wnt11, enabling robust activation of non-canonical Wnt pathways, while also binding Wnt3A for canonical signaling. The CRD determines ligand-binding affinity and specificity, making it a target for therapeutic intervention [@antalis2010].

Seven-Transmembrane Domain

FZD10 contains seven hydrophobic transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The transmembrane domain adopts the canonical GPCR fold and can couple to heterotrimeric G proteins upon ligand binding. FZD10 exhibits coupling to multiple G protein subtypes depending on cellular context, including Gαs for cAMP signaling, Gαq for PLC activation, and Gαi/o for downstream effects on PI3K/Akt signaling.

C-terminal Tail

The intracellular C-terminal tail contains a PDZ domain-binding motif (Ser/Thr-X-Ser/Thr-X-φ) that enables interaction with Dishevelled (DVL) adaptor proteins and other signaling components including scaffold proteins and regulatory enzymes. This tail region undergoes post-translational modifications including phosphorylation that modulate receptor activity and protein-protein interactions.

Wnt Signaling Pathways Activated by FZD10

Canonical Wnt/β-catenin Pathway

FZD10 activates the canonical Wnt/β-catenin pathway through ligand binding and receptor complex formation:

Receptor Activation: Wnt ligand binding to the FZD10 CRD initiates receptor oligomerization and recruitment of cytoplasmic signaling proteins. FZD10 forms receptor complexes with co-receptors LRP5 or LRP6, which are required for full pathway activation. The FZD10-LRP5/6 complex internalized into signaling endosomes creates a platform for downstream signal transduction.

Signalosome Formation: Upon activation, FZD10 recruits Dishevelled (DVL1, DVL2, DVL3) proteins through interactions between the C-terminal tail of FZD10 and the PDZ domain of DVL. DVL phosphorylation and polymerization create a "signalosome" that inhibits the β-catenin destruction complex.

β-catenin Stabilization: FZD10-activated DVL disrupts the destruction complex containing APC, AXIN1/2, GSK3β, and CK1α, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it associates with TCF/LEF transcription factors.

Non-Canonical Wnt Pathways

FZD10 also activates non-canonical Wnt pathways:

Wnt/PCP Pathway: The planar cell polarity pathway regulates cytoskeletal dynamics, cell polarity, and tissue patterning. FZD8 activation recruits DVL and activates small GTPases including RAC1 and RHOA, leading to effects on actin cytoskeleton organization, cell migration, and neuronal morphogenesis.

Wnt/Ca²⁺ Pathway: FZD10 can activate downstream signaling through Gαq-coupled phospholipase C (PLC) activation, leading to intracellular Ca²⁺ release and activation of Ca²⁺-dependent kinases including CaMKII and PKC.

FZD10 in Nervous System Development

Neural Development Expression

FZD10 exhibits developmental stage-specific expression in the nervous system:

• Embryonic neural tube: High expression in developing neuroepithelium
• Cortical development: Expression in ventricular zone neural progenitors
• Hippocampal formation: Expression in dentate gyrus progenitors
• Cerebellar development: Expression in external germinal layer

Neuronal Differentiation

FZD10 signaling promotes neuronal differentiation from neural stem cells:

• Wnt/FZD10 signaling activates proneural gene expression (ASCL1, NEUROD1)
• FZD10 regulates cell cycle exit of neural progenitors
• Wnt/β-catenin promotes expression of neuronal differentiation markers
• Non-canonical FZD10 signaling modulates cytoskeletal reorganization during neuritogenesis

Synaptic Development

While less studied than other Frizzled receptors, FZD10 likely contributes to synaptic development:

• Wnt signaling generally promotes excitatory synapse formation
• FZD10 may regulate presynaptic vesicle cycling
• Postsynaptic FZD10 could influence dendritic spine morphogenesis

FZD10 in Alzheimer's Disease

Emerging evidence links FZD10 and Wnt signaling to Alzheimer's disease pathogenesis:

Wnt Pathway Dysregulation in AD

Post-mortem studies and model systems reveal:

• Altered FZD10 expression in AD brain regions [@inestrosa2013]
• Reduced canonical Wnt signaling in AD hippocampus
• Increased Wnt antagonist expression (DKK1, SFRP)
• Correlation between Wnt pathway activity and cognitive function

Amyloid-β and FZD10

FZD10 signaling interacts with amyloid-β pathology:

• Amyloid-β inhibits Wnt/FZD10 signaling through multiple mechanisms
• Wnt/FZD10 signaling protects against amyloid-β-induced synaptic toxicity
• FZD10 activation may promote amyloid-β clearance
• Combination of Wnt activation and anti-amyloid therapies shows promise

Tau Pathology

Wnt/FZD10 signaling intersects with tau pathology:

• GSK3β links both Wnt signaling and tau phosphorylation
• FZD10 activation can modulate tau phosphorylation status
• Wnt pathway modulation reduces tau pathology in models
• FZD10 dysfunction may contribute to tau propagation

Therapeutic Implications

Modulating FZD10 represents a potential AD therapeutic strategy:

• Wnt pathway activators could restore neuronal function
• FZD10-selective modulators may reduce off-target effects
• Gene therapy approaches for sustained Wnt activation
• Biomarker development for patient selection

FZD10 in Parkinson's Disease

FZD10 and Wnt signaling have implications for Parkinson's disease:

Dopaminergic Neuron Biology

FZD10 may contribute to dopaminergic neuron function:

• Wnt signaling during development specifies midbrain dopamine neurons
• Adult FZD10 expression in [substantia nigra](/brain-regions/substantia-nigra) pars compacta
• FZD10 signaling promotes dopaminergic neuron survival
• Age-related Wnt dysregulation may contribute to vulnerability

Mitochondrial Function

FZD10 intersects with mitochondrial dysfunction in PD:

• Wnt signaling regulates PGC-1α and mitochondrial biogenesis
• FZD10 activation protects against mitochondrial toxins
• PINK1/Parkin pathway modulates Wnt signaling
• FZD10-based strategies may improve mitochondrial function

Alpha-Synuclein

The relationship between alpha-synuclein and FZD10:

• Wnt signaling protects against alpha-synuclein-induced toxicity
• FZD10 activation reduces alpha-synuclein aggregation
• Alpha-synuclein pathology disrupts Wnt signaling
• Targeting both pathways may provide synergistic benefits

Clinical Implications

FZD10-based approaches for PD:

• Small molecule Wnt/FZD10 activators
• Gene therapy for sustained expression
• Neuroprotective strategies
• Disease-modifying potential

FZD10 in Amyotrophic Lateral Sclerosis

FZD10 and Wnt signaling dysregulation in ALS:

Wnt Pathway Alterations

Studies of ALS tissue and models reveal:

• Altered FZD expression in spinal cord
• Reduced Wnt signaling in motor cortex
• Dysregulated Wnt target genes
• Correlation with disease progression [@garrido2019]

Motor Neuron Vulnerability

FZD10 may relate to selective motor neuron vulnerability:

• Motor neurons require Wnt signaling for survival
• Age-related decrease in Wnt signaling
• ALS mutations affect Wnt pathway components
• Restoring FZD10 signaling may protect motor neurons

FZD10 in Cancer (Historical Context)

While this section focuses on neurodegeneration, FZD10 was first characterized in cancer:

Synovial Sarcoma

FZD10 is frequently overexpressed in synovial sarcoma:

• Characteristic of SS18-SSX fusion-positive tumors
• Promotes tumor cell proliferation and survival
• Therapeutic target potential with monoclonal antibodies
• Prognostic marker in some studies [@xie2021]

Other Cancers

FZD10 expression in other malignancies:

• Colorectal cancer
• Breast cancer
• Pancreatic cancer
• Gliomas

Expression Pattern

FZD10 exhibits tissue-specific and development-specific expression:

Brain Regions:

• Cerebral Cortex: Expression in select neuronal populations
• Hippocampus: Expression in dentate gyrus
• Cerebellum: Expression in Purkinje cells
• Substantia Nigra: Low to moderate expression
• Spinal Cord: Expression in motor neurons

• Neurons: Expression in excitatory neurons
• Neural Stem Cells: High in progenitor populations
• Astrocytes: Low baseline expression
• Glioblastoma: High expression in some tumors

• Embryonic: High expression in developing nervous system
• Postnatal: Decreasing expression
• Adult: Low to moderate expression

Protein Interactions

FZD10 interacts with multiple proteins:

Wnt Ligands

Co-receptors

• LRP5/6: Canonical Wnt co-receptors
• ROR1/2: Alternative co-receptors

Intracellular Proteins

• DVL1/2/3: Primary downstream effectors
• GSK3β: Kinase in Wnt and disease pathways
• β-catenin: Transcriptional co-activator
• AXIN1/2: Regulatory components

Genetic Variants

FZD10 genetic variants in neurodegenerative diseases:

Alzheimer's Disease

• Limited direct evidence for FZD10 variants
• Chromosome 12q region shows some association signals
• Expression studies suggest regulatory variant effects
• Further investigation needed

Parkinson's Disease

• No strong evidence for FZD10 risk variants
• Wnt pathway genes in aggregate show associations
• May be relevant in combination with other genes

Therapeutic Targeting

FZD10 as a therapeutic target:

Agonist Approaches

• Wnt ligand-based therapies
• Small molecule activators
• FZD10-selective antibodies
• Advantages: pathway restoration
• Challenges: balancing canonical vs. non-canonical signaling

Gene Therapy

• Viral vector delivery
• CRISPR activation approaches
• Advantages: sustained expression
• Challenges: appropriate expression levels

Considerations

• Pathway specificity and balance
• Cell-type targeting
• Temporal window of intervention
• Cancer risk with chronic activation

Biomarkers

FZD10 as a biomarker:

Fluid Biomarkers

• Soluble FZD10 in CSF: under investigation
• Correlation with disease stage
• Potential for patient stratification

Expression Biomarkers

• FZD10 mRNA in brain tissue
• Wnt pathway activity markers
• Combination with other biomarkers

Animal Models

Mouse Models

• Fzd10 knockout: developmental phenotypes
• Transgenic models: gain-of-function studies
• Disease models: AD, PD, ALS with FZD10 modulation

Disease Model Studies

• AD models with FZD10 manipulation
• PD models with Wnt pathway modulation
• ALS models with FZD10 assessment

Future Directions

Research priorities for FZD10 in neurodegeneration:

Basic Science

• Detailed expression mapping in human brain
• Cell-type specific signaling mechanisms
• Interaction with disease-specific pathological proteins
• Temporal dynamics of pathway dysregulation

Therapeutic Development

• Brain-penetrant FZD10 modulators
• Pathway-selective compounds
• Combination therapy strategies
• Safety considerations

Clinical Translation

• Biomarker development
• Patient selection criteria
• Efficacy endpoints
• Regulatory pathways

Summary

FZD10 serves as a Wnt receptor with important functions in neural development and emerging relevance to neurodegenerative diseases. While best characterized in cancer biology, particularly synovial sarcoma, FZD10 plays roles in neural stem cell biology, neuronal differentiation, and synaptic function in the developing and adult nervous system. Dysregulated FZD10 expression and Wnt signaling alterations contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and ALS, intersecting with core pathological features including protein aggregation, mitochondrial dysfunction, and neuroinflammation. The therapeutic targeting of FZD10 and Wnt signaling represents a promising strategy for disease modification in neurodegenerative conditions, though significant challenges remain in developing brain-penetrant, pathway-specific modulators with appropriate safety profiles. Continued investigation of FZD10 biology in the context of neurodegeneration offers substantial potential for advancing treatment strategies for these devastating disorders.

FZD10 in Tauopathies

Beyond AD, FZD10 and Wnt signaling are relevant to other tauopathies including [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), [corticobasal degeneration](/diseases/corticobasal-syndrome), and [frontotemporal dementia](/diseases/frontotemporal-dementia):

PSP and CBD

• Reduced Wnt signaling in PSP and CBD brains
• FZD expression alterations in affected brain regions
• GSK3β overactivity linking Wnt and tau pathology
• Therapeutic targeting rationale

FTD Spectrum

• Wnt pathway genes implicated in GWAS
• FZD10 expression in frontotemporal regions
• Interaction with tau and TDP-43 pathology
• Emerging therapeutic strategies

FZD10 in Neuroinflammation

Wnt/FZD10 signaling modulates neuroinflammatory responses:

Microglial Function

• FZD10 expression in microglia
• Wnt signaling regulates microglial activation
• Anti-inflammatory effects of canonical Wnt
• Therapeutic modulation potential [@marchetti2018]

Astrocyte Interactions

• FZD10 in astrocyte function
• Wnt signaling in astrogliosis
• Neuron-astrocyte communication
• Implications for disease progression

Therapeutic Implications

• Reducing chronic neuroinflammation
• Promoting neuroprotective phenotypes
• Combination with disease-modifying approaches

FZD10 and Synaptic Function

FZD10 contributes to synaptic biology:

Synaptic Development

• Roles in excitatory synapse formation
• Presynaptic functions
• Postsynaptic plasticity
• Activity-dependent regulation

Synaptic Dysfunction in Disease

• Wnt pathway alterations in synaptic failure
• FZD10 in synaptic deficits
• Therapeutic restoration potential

FZD10 in Neurogenesis

Adult neurogenesis and FZD10:

Hippocampal Neurogenesis

• FZD10 in dentate gyrus progenitors
• Wnt regulation of neurogenesis
• Age-related changes
• Therapeutic enhancement potential

Subventricular Zone

• FZD10 in SVZ neural stem cells
• Wnt in olfactory bulb neurogenesis
• Disease-related alterations

FZD10 in Mitochondrial Biology

Wnt/FZD10 intersects with mitochondrial function:

Mitochondrial Dynamics

• Wnt regulation of fusion/fission
• FZD10 in mitochondrial trafficking
• PGC-1α and biogenesis
• Disease implications

Bioenergetics

• Metabolic requirements
• Wnt in energy metabolism
• Implications for neuronal survival

FZD10 in Axonal Transport

FZD10 and Wnt signaling in axonal transport:

Development

• Axon guidance roles
• Growth cone dynamics
• Cytoskeletal regulation

Disease

• Transport deficits in neurodegeneration
• FZD10 in axonal pathology
• Therapeutic targeting

FZD10 and Protein Quality Control

FZD10 intersects with proteostasis:

Autophagy

• Wnt/FZD10 in autophagy regulation
• Clearance of pathological proteins
• Therapeutic implications

Proteasome

• Wnt signaling in proteasome function
• Protein clearance pathways
• Disease-related alterations

FZD10 in Oxidative Stress

Wnt/FZD10 and oxidative stress:

Antioxidant Response

• Nrf2 pathway interaction
• FZD10 in oxidative stress response
• Protective mechanisms

Disease Relevance

• Oxidative stress in neurodegeneration
• FZD10 modulation potential
• Therapeutic strategies

FZD10 in Aging

Age-related changes in FZD10:

Expression Changes

• Decreased FZD10 with age
• Regional vulnerabilities
• Implications for neuronal function

Signaling Alterations

• Wnt pathway dysregulation
• Cellular consequences
• Therapeutic implications

FZD10 in Glial Function

FZD10 in non-neuronal cells:

Astrocytes

• Expression and function
• Support of neuronal health
• Disease-related changes

Oligodendrocytes

• FZD10 in myelination
• White matter relevance
• Disease implications

Microglia

• Neuroimmune modulation
• Inflammatory responses
• Therapeutic targeting

Biomarker Potential

FZD10 as a biomarker:

Diagnostic Biomarkers

• FZD10 expression in disease
• Fluid biomarker development
• Imaging biomarkers

Prognostic Biomarkers

• Disease progression markers
• Treatment response indicators
• Patient stratification

Therapeutic Development

FZD10-targeted therapies:

Small Molecules

• Wnt pathway activators
• FZD10-selective compounds
• Development challenges

Biological Therapies

• Wnt ligand therapies
• Antibody-based approaches
• Gene therapy strategies

Combination Approaches

• With amyloid-targeting (AD)
• With dopaminergic therapies (PD)
• With anti-inflammatory approaches

Challenges and Considerations

Pathway Specificity

• Canonical vs. non-canonical balance
• Cell-type specific effects
• Temporal considerations

Safety Concerns

• Cancer risk with Wnt activation
• Off-target effects
• Long-term safety

Delivery

• Brain penetration
• Cellular targeting
• Sustained expression

Animal Models

Transgenic Models

• FZD10 overexpression
• Knockout studies
• Conditional models

Disease Models

• AD models with FZD10
• PD models
• ALS models

Research Gaps

Basic Science

• Human brain expression
• Cell-type specificity
• Disease mechanisms

Clinical Translation

• Biomarker validation
• Therapeutic development
• Clinical trials

Future Directions

Near-term

• Expression studies
• Mechanism elucidation
• Therapeutic screening

Long-term

• Clinical development
• Combination strategies
• Personalized approaches

Cross-Links

• [Wnt Signaling Pathway](/mechanisms/wnt-signaling-neurodegeneration)
• [FZD7 Gene](/genes/fzd7)
• [FZD8 Gene](/genes/fzd8)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
• [Tauopathies](/mechanisms/tauopathies)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-cause-vs-consequence)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Pathway & Interaction Diagram

Interactive diagram showing FZD10's key relationships in the SciDEX knowledge graph (5 connections shown).

References